Friday, September 25, 2026
ExploreSearch
Via News
MarketIndexes

Nikkei 225 Over 5% Up In The Last 10 Sessions

ViaNews Editorial Team

October 2, 2024

Nikkei 225 Over 5% Up In The Last 10 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.32% for the last 10 sessions. At 21:08 EST on Tuesday, 1 October, Nikkei 225 (N225) is $38,128.43.

Concerning Nikkei 225's yearly highs and lows, it's 25.06% up from its 52-week low and 10.13% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was a positive 0.50%, a negative 0.01%, and a positive 1.72%, respectively.

Nikkei 225's highest amplitude of average volatility was 3.02% (last week), 1.61% (last month), and 1.72% (last quarter), respectively.

More news about Nikkei 225 (N225).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesN225Nikkei 225Price UpINDICES Price UpIndex Nowintelligent
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com